News

Why Is DexCom (DXCM) In Focus After Its G7 Trial Reached NEJM?

DexCom (NasdaqGS:DXCM) reported that results from the CONNECT randomized controlled trial of its G7 CGM were published in The New England Journal of Medicine. The CONNECT study focused on adults with Type 2 diabetes who are not using insulin and assessed clinical outcomes with standalone real time CGM. Researchers reported significant clinical benefits in glycemic control for this group when using DexCom's G7 continuous glucose monitoring system. The NEJM publication of the CONNECT trial for...

Yahoo·21:17DXCM

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study

DXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with Type 2 diabetes, supporting CGM adoption.

Yahoo·09:50DXCM

DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives

DexCom (DXCM) stock outlook: G7 15-Day cuts CGM costs, lifts margins; NEJM CONNECT supports expansion.

SeekingAlpha·19:41DXCM

Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin

SAN DIEGO, October 14, 2026--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the significant benefits of continuous glucose monitoring (CGM) for adults with Type 2 diabetes not on insulin.

Yahoo·17:10DXCM

DexCom's CONNECT Study Published In The New England Journal Of Medicine; Findings Support The Role Of CGM Earlier In Type 2 Diabetes Care For All People, Including Those Over The Age Of 65

Publication marks the first time in nearly two decades that The New England Journal of Medicine has published clinical data on standalone real-time continuous glucose monitoring (CGM) technology, dating back to the

Benzinga·13:13DXCM

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

DexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, forex and input-price pressures pose risks.

Yahoo·12:41DXCM

mHealth Solutions Market Forecasts Growth from $109.05B (2026) to $275.44B by 2031, Profiling Philips, Medtronic, Abbott, Dexcom, ResMed & 20 Other Key Players

388-Page Report Delivers 2025 Market Share Rankings, Vendor Valuation Metrics and End-User Buying Criteria as Asia Pacific Emerges as the Fastest-Growing RegionDublin, Oct. 13, 2026 (GLOBE NEWSWIRE) -- "mHealth Solutions Market: Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. Global mHealth Solutions Market to Reach USD 275.44 Billion by 2031 The global mHealth solutions market is projected to grow from USD 109.05 billion in 2026 to USD 275.44 billion by 2031, regis

Yahoo·11:20DXCM

DexCom (NASDAQ:DXCM): Affordable Growth at a Reasonable Valuation

DexCom (DXCM) offers affordable growth with strong EPS outlook, high profitability, and reasonable peer valuation—making it a quality growth pick.

ChartMill·07:21DXCM

Here's What to Expect From DexCom’s Next Earnings Report

DexCom will unveil its third-quarter results soon, with analysts expecting EPS to post a high-single-digit year-over-year gain.

Yahoo·06:27DXCM

BTIG Maintains Buy on DexCom, Raises Price Target to $96

BTIG analyst Ryan Zimmerman maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $90 to $96.

Benzinga·01:57DXCM

Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time

SAN DIEGO, October 07, 2026--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2026 financial results after market close on Thursday, October 29, 2026. Management will hold a conference call to review the company's third quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and wil

Yahoo·08:30DXCM

Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading

SAN DIEGO, October 06, 2026--DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the company’s one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.

Yahoo·09:00DXCM

DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care

Dexcom sees room to expand CGM adoption as low awareness, reimbursement hurdles and rising GLP-1 use create new opportunities in Type 2 diabetes.

Yahoo·10:00DXCM

DexCom (NASDAQ:DXCM): Strong Growth Paired With a High-Quality Technical Setup

DexCom shows strong growth, top-tier profitability, and a constructive chart setup, making it a standout pick for growth screens with defined technical levels.

ChartMill·07:00DXCM

RBC Capital Maintains Outperform on DexCom, Raises Price Target to $105

RBC Capital analyst Kendall Au maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the price target from $90 to $105.

Benzinga·05:04DXCM

Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care

MILAN, September 28, 2026--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its "Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology" in advance of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28-Oct. 2. The company also announced a partnership to become the official continuous glucose monitor of Team Novo Nordisk.

Yahoo·02:00DXCM

Dexcom Becomes Team Novo Nordisk's Official CGM Partner, Releases Report Citing Three Type 2 Care Challenges Across Eight Countries

New global State of Type 2 Report uncovers three interconnected challenges in Type 2 diabetes care: health literacy, technology literacy and systemic access.1New partnership reinforces Dexcom’s commitment to advancing

Benzinga·23:17DXCM

DexCom (DXCM) Stock Looks Cheap Based On Future Cash Flow

DexCom shares have delivered a mixed ride in recent years, and that uneven path raises a simple question for anyone looking at the chart today. Is the current US$87.47 price adequately supported by the cash the business is expected to generate over time? Over the past 5 years the stock has declined 36.0%, which puts the focus squarely on whether the cash flow story still lines up with the share price. The recent move to expand Jereme Sylvain’s remit to Chief Operating Officer as well as...

Yahoo·20:20DXCM

Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced?

DexCom (DXCM) just reshuffled its leadership team, with longtime finance chief Jereme Sylvain stepping into a combined EVP and Chief Operating Officer role that now includes responsibility for global operations and quality. Recent boardroom moves at DexCom have arrived at a time when the 90-day share price return of 27.79% and year-to-date gain of 31.85% point to building momentum. However, the 1-year total shareholder return of 29.97% contrasts with a weaker 3-year record and a deeper 5-year...

Yahoo·00:29

DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer

DexCom (NasdaqGS:DXCM) has promoted former Chief Financial Officer Jereme Sylvain to EVP and Chief Operating Officer. Healthcare executive Glenn S. Boehnlein has joined DexCom's board of directors, adding external industry experience to governance. The leadership shift, including Sylvain's promotion and Boehnlein's board appointment, deserves weighing alongside DexCom's broader fundamentals and risks. Take a look at 3 other big wins we have identified for DexCom. For readers looking to...

Yahoo·18:13DXCM

Truist Securities Maintains Buy on DexCom, Raises Price Target to $102

Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $93 to $102.

Benzinga·08:49DXCM

TD Cowen Reiterates Buy on DexCom, Maintains $95 Price Target

TD Cowen analyst Joshua Jennings reiterates DexCom (NASDAQ:DXCM) with a Buy and maintains $95 price target.

Benzinga·06:54DXCM

2 Unpopular Stocks That Should Get More Attention and 1 We Question

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Dexcom gives CFO Jereme Sylvain expanded role

Sylvain will work as chief operating officer of the diabetes technology company while continuing as its CFO.

Yahoo·23:33DXCM

Dexcom Promotes Jereme Sylvain to Chief Operating Officer

SAN DIEGO, September 14, 2026--Dexcom Promotes Jereme Sylvain to Chief Operating Officer

Yahoo·16:30DXCM

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.

Yahoo·14:44DXCM

Dexcom Appoints Glenn Boehnlein to Board of Directors

SAN DIEGO, September 10, 2026--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026.

Yahoo·16:15DXCM

3 Quality Compounders with Impressive Fundamentals

A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits at high returns.

Yahoo·11:21

DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

DexCom, Inc. (DXCM) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDTCompany ParticipantsJereme Sylvain - Executive VP, CFO &...

SeekingAlpha·07:17DXCM

DexCom Stock: Is DXCM Underperforming the Healthcare Sector?

DexCom has underperformed the broader market over the past year, while analysts remain strongly optimistic about its future prospects.

Yahoo·08:36DXCM

DexCom (DXCM) Stock Looks Undervalued On Fair Value While Earnings Look Fair

DexCom stock has delivered a mixed ride for long term holders, with the share price down about 35.1% over five years even as a Discounted Cash Flow (DCF) estimate points to an intrinsic value that sits meaningfully above the current market price. At the same time, broader valuation checks lean cautious and market based multiples look roughly in line with peers rather than clearly cheap. Over the past five years, DexCom shareholders have seen the stock decline about 35.1%, which puts more...

Yahoo·03:19DXCM

Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including DexCom (NASDAQ:DXCM) and its peers.

Yahoo·15:27DXCM

Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services

Reviewing prior stock picks is how investors turn experience into valuable feedback. A recommendation is only a thesis until the market tests it. Watch Doug discuss recent stock picks, provide input on the current market environment—and take your questions.

Yahoo·01:51DXCM

3 Reasons DXCM Has Explosive Upside Potential

Over the past six months, DexCom has been a great trade, beating the S&P 500 by 11.5%. Its stock price has climbed to $91.17, representing a healthy 23.6% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Yahoo·11:18DXCM

Dexcom Announces Upcoming Conference Presentation

SAN DIEGO, September 01, 2026--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026.

Yahoo·09:30DXCM

Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth Today

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Yahoo·09:30DXCM

DexCom (NASDAQ:DXCM): An Affordable Growth Play With Strong Momentum and Fair Valuation

Discover why DexCom (DXCM) fits the Affordable Growth screen, balancing strong earnings growth with reasonable valuation and solid financial health.

ChartMill·07:21DXCM

FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.

Benzinga·05:36

The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products

Embecta (EMBC) looks like a deep value buy: P/E under 3x, 50%+ FCF yield, insider buying and rebound setup.

SeekingAlpha·19:11

1 Healthcare Stock to Target This Week and 2 Facing Headwinds

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 27.5% gain over the past six months, beating the S&P 500 by 16.2 percentage points.

Yahoo·08:47

Dexcom (NASDAQ:DXCM) Combines Strong Growth With a Bullish Technical Setup

Dexcom (DXCM) passes strong growth & technical screens with high scores, solid fundamentals, and a bull flag breakout setup.

ChartMill·07:31DXCM

DexCom (DXCM) Stock May Trade At A 37% Discount On Cash Flow

DexCom stock has gained 33.4% year to date, yet the valuation picture is mixed, with the intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to meaningful upside while the broader checks lean less generous. For investors, the question is how to weigh a DCF signal that suggests the shares trade at a discount against a low overall value score. Year to date, DexCom is up 33.4%, which puts more pressure on the current price to be supported by future cash flows. Expectations...

Yahoo·22:08DXCM

DexCom (DXCM) Rebounds On Growth Hopes, Does It Look Fully Valued?

DexCom stock reacts to recent performance and fundamentals DexCom (DXCM) has attracted investor attention after a recent share price move, with the stock closing at US$89.75. The company’s returns over the past month and past 3 months now stand out against its longer term record. See our latest analysis for DexCom. Short term momentum in DexCom has been strong, with the 30 day share price return of 17.09% and the 90 day share price return of 34.06% contrasting with a more modest 1 year total...

Yahoo·11:16

DexCom (DXCM) Stock Sees Modest Fair Value Lift After Q2 And Clinical Updates

DexCom’s latest analyst work shows a modest lift in the modelled fair value, with the price target figure moving from US$91.64 to US$94.12. This adjustment sits alongside mixed analyst commentary that balances positive Q2 2026 execution, new clinical data and guidance updates, and ongoing questions about valuation and sector sentiment. As you read on, you will see how these moving parts shape the current story around DexCom and how to keep track of future shifts in the narrative. Stay updated...

Yahoo·04:09DXCM

1 Surging Stock Worth Your Attention and 2 We Question

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

Yahoo·06:37

1 Growth Stock to Stash and 2 We Brush Off

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

Yahoo·19:49

1 S&P 500 Stock on Our Buy List and 2 We Avoid

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

Yahoo·17:01

Is Wall Street Bullish or Bearish on DexCom Stock?

Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Yahoo·12:42DXCM

Here's How Much You'd Have If You Invested $1000 in DexCom a Decade Ago

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Yahoo·08:30DXCM

Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?

DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valuation, competition and litigation temper upside.

Yahoo·14:36DXCM

DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?

DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.

Yahoo·14:34DXCM

DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here?

DexCom's 52.5% three-month rally is backed by earnings growth and margin gains, but premium valuation, competition and litigation raise the bar.

Tracking Baillie Gifford's 13F Portfolio - Q2 2026 Update

Baillie Gifford Q2 2026 13F: portfolio grew to $110B; SpaceX IPO (SPCX) tops holdings, NVDA added, AMZN trimmed. Read more analysis here.

SeekingAlpha·16:54

DexCom (NASDAQ:DXCM) Stands Out as an Affordable Growth Stock

DexCom earns a 7/10 fundamental rating, blending strong growth, reasonable valuation, and solid profitability as an affordable growth pick.

ChartMill·07:10DXCM